ApoB and Lp(a): The Two Cholesterol Tests Midlife Women Should Ask For

Because estrogen is a lipid regulator, and losing it changes how your body handles cholesterol — quickly, and in a specific window.

Estrogen upregulates LDL receptors in the liver. Those receptors are what pull LDL particles out of the bloodstream and clear them. More estrogen means more receptors and faster clearance; less estrogen means fewer receptors and LDL particles that circulate longer. Estrogen also influences triglyceride handling and HDL composition.

What makes this more than a theoretical mechanism is the timing evidence from SWAN. Analyses led by Matthews and colleagues (*Journal of the American College of Cardiology*, 2009) asked a specific question: are the cardiovascular changes in midlife women driven by getting older, or by the menopause transition itself? For most risk factors — blood pressure, insulin, glucose — the changes tracked chronological aging. But total cholesterol, LDL cholesterol, and apolipoprotein B rose substantially within the one-year interval surrounding the final menstrual period, in a pattern consistent with the hormonal transition rather than gradual aging.

That finding matters practically. It means the shift is not slow drift you can watch indefinitely. It is a step change concentrated around a specific point, which is why so many women get a genuinely surprising cholesterol result in their late forties or early fifties after decades of normal panels — and why 'it's just age' is an inadequate explanation.

It also means the years around your final period are the moment to establish a proper baseline rather than the moment to reassure yourself. Our companion pieces on [why LDL rises after 45](/blog/menopause-and-cholesterol-why-ldl-rises-after-45) and [metabolic syndrome in menopause](/blog/metabolic-syndrome-in-menopause-swan-data-explained) cover the wider metabolic picture this sits inside.

Apolipoprotein B (ApoB) is a protein that sits on the surface of every atherogenic lipoprotein particle — LDL, VLDL, IDL, and Lp(a). Crucially, there is exactly one ApoB molecule per particle. So measuring ApoB gives you a direct count of how many artery-damaging particles are circulating.

Why that is better than LDL cholesterol takes one analogy. LDL-C measures the *cargo* — how much cholesterol is being carried. ApoB measures the *vehicles* — how many particles are doing the carrying. Two people can carry identical cargo in very different numbers of vehicles.

This matters because atherosclerosis is driven by particles physically entering the artery wall. A small, dense LDL particle carries less cholesterol than a large buoyant one, but it is just as capable of penetrating the endothelium. Someone with many small particles can have a reassuring LDL-C and a genuinely elevated particle count — a state called discordance. Discordance is more common in people with insulin resistance, elevated triglycerides, low HDL, or central adiposity, which describes a substantial share of midlife women.

That is precisely the pattern menopause tends to produce. As visceral fat increases and insulin sensitivity declines through the transition, LDL particles shift smaller and denser. Your LDL-C might rise modestly while your particle count rises more — and only ApoB shows you that.

General reference points used in prevention: under 90 mg/dL is a common primary-prevention target, with under 80 or under 65 mg/dL used for people at higher risk or with established disease. Population averages sit well above these, so 'normal for the lab' is not the same as 'optimal for your arteries.' Targets are individual and belong in a conversation with your clinician.

Lipoprotein(a) — pronounced 'L-P-little-a' — is an LDL-like particle with an extra protein, apolipoprotein(a), attached. That addition makes it both more atherogenic and more prothrombotic than ordinary LDL, meaning it contributes to plaque formation and to clot risk.

Three things make Lp(a) unusual among lipid markers.

It is largely genetic. Your Lp(a) level is roughly 80-90% determined by inheritance and is essentially set for life. It does not respond meaningfully to diet, exercise, or weight loss, and statins do not lower it (they may raise it slightly).

It only needs testing once. Because the level is stable, a single measurement in adulthood tells you what you need to know. This is a genuinely unusual proposition in preventive medicine and one reason it is worth asking for.

It is common enough to matter. Roughly one in five people has an elevated level — commonly defined as above 50 mg/dL or above 125 nmol/L, though the nmol/L assay is preferred because it counts particles rather than mass.

The menopause connection is direct. Estrogen lowers Lp(a); analyses from hormone therapy trials including HERS and the WHI found that oral estrogen reduced Lp(a) levels meaningfully. The corollary is that losing endogenous estrogen at menopause tends to move Lp(a) in the wrong direction. This is not a reason to take hormone therapy for cardiovascular prevention — that is not what HRT is indicated for, and our guide to [starting HRT after 60](/blog/starting-hrt-after-60-is-it-too-late) covers where the timing evidence actually sits — but it does explain why a marker you may have never thought about becomes relevant now.

Knowing an elevated Lp(a) changes management. It typically prompts more aggressive control of everything you *can* modify — ApoB, blood pressure, smoking — and it flags your first-degree relatives for testing, since it is inherited.

This is the part most women are never told: cardiovascular risk calculators built on general populations systematically miss risk that is specific to female reproductive history — and the guidelines themselves acknowledge it.

The 2018 AHA/ACC Cholesterol Guideline introduced the concept of risk-enhancing factors: conditions that shift treatment decisions upward when calculated risk sits in an intermediate range. Several are female-specific:

• •Premature menopause (before age 40), including surgical menopause
• •History of preeclampsia or other pregnancy-associated hypertensive disorders
• •Elevated Lp(a), at or above 50 mg/dL
• •Elevated ApoB, at or above 130 mg/dL
• •Persistently elevated triglycerides, chronic inflammatory conditions, chronic kidney disease, metabolic syndrome, and South Asian ancestry

If any of these apply to you, they are meant to be weighed in the decision — not filed as background history. A woman who went through menopause at 38, or who had preeclampsia in her thirties, carries risk that a standard ten-year calculator will underestimate. Our article on [premature ovarian insufficiency](/blog/premature-ovarian-insufficiency-early-menopause-before-40) covers why early menopause carries long-term cardiovascular and skeletal consequences.

A further tool worth knowing about is the coronary artery calcium (CAC) score — a low-dose CT that directly measures calcified plaque. It is particularly useful when the decision about starting a statin is genuinely uncertain: a score of zero is strongly reassuring and can justify deferring treatment, while a substantial score reclassifies risk upward regardless of what the calculator said. It involves a small radiation dose and is not always covered by insurance, so it is a discussion rather than a default.

The practical upshot: bring your reproductive history to your cardiovascular appointment. Age at final period, pregnancy complications, and family history are data, and they belong in the risk conversation.

Usually by asking for them by name. Neither is included in a standard lipid panel, and in most systems neither is ordered unless requested or unless you already have a flagged risk profile.

Practical points that make the request easier:

ApoB does not require fasting. Nor, in most modern guidance, does a standard lipid panel. If fasting is inconvenient, say so — non-fasting results are acceptable for risk assessment in the great majority of cases.

Lp(a) should be ordered in nmol/L where available. The two units are not interchangeable and cannot be reliably converted, because mg/dL measures mass while nmol/L counts particles, and particle size varies between people. If your lab reports mg/dL, that is still usable — just note which unit your result is in.

Timing matters slightly. Lipids can be temporarily distorted by acute illness, recent infection, or major weight change. If you are in a period of rapid weight loss — on a GLP-1, for instance — lipids are actively moving, and a single snapshot is less informative than a trend. Our piece on [GLP-1s and cholesterol in menopause](/blog/glp1-and-cholesterol-in-menopause-what-happens-to-your-lipids) covers what typically happens to lipids during that period.

How to frame the ask. Something like: *'Given that LDL and ApoB rise around the menopause transition, I'd like an ApoB with my lipid panel, and a one-time Lp(a) since it's genetic and only needs testing once.'* That framing states the rationale and the frequency, which tends to move the conversation faster than a general request for 'more tests.'

If your clinician declines, ask what would change their mind — a family history of premature cardiovascular disease in a first-degree relative, an intermediate calculated risk score, or elevated triglycerides are all reasonable triggers. Both tests are also widely available through direct-to-consumer laboratory services in many regions if you would rather not wait, though interpreting the result without clinical context is not advisable.

A great deal — and it is worth separating what moves each marker, because the answers differ.

ApoB responds to almost everything that lowers LDL. Reducing saturated fat, increasing soluble fiber (oats, legumes, psyllium), and adding plant sterols all lower particle count modestly. Losing visceral fat improves the small-dense-particle pattern specifically. Statins lower ApoB substantially; ezetimibe, bempedoic acid, and PCSK9 inhibitors are further options where indicated. If a statin is on the table, our article on [the midlife medicine cabinet](/blog/glp1-hrt-statins-midlife-medicine-cabinet-timing-guide) covers how it fits alongside other medications.

Lp(a) barely responds to lifestyle at all, and this is important to hear clearly so you do not spend years attributing an unchanged number to insufficient effort. Diet, exercise, and weight loss do not meaningfully lower it. Statins do not lower it. Targeted Lp(a)-lowering therapies are in late-stage clinical development but are not yet standard care. What an elevated Lp(a) *does* change is urgency: it justifies driving ApoB lower, controlling blood pressure tightly, and testing first-degree relatives.

Exercise deserves specific mention because midlife women are consistently under-prescribed the type that matters most. Resistance training improves insulin sensitivity and body composition, both of which improve the particle profile — see our [resistance training protocol for menopause](/blog/resistance-training-for-menopause-the-bone-density-protocol). Aerobic training improves triglycerides and HDL function. Neither replaces medication when medication is indicated, and neither is optional.

The most useful reframe: menopause does not cause heart disease, but it does mark the point where risk that was previously masked becomes visible and modifiable. Cardiovascular disease remains the leading cause of death in women, and the decade around the transition is when the trajectory is most changeable. Getting two additional numbers on a lab slip is a small ask for that much clarity.

This article is educational and is not medical advice; testing and treatment decisions belong with your own clinician.